≡ Risteys
FG R12 + FR

Documentation Changelog GitHub Contact & Feedback

Carcinoma in situ of larynx

Endpoint Browser PheWeb

CD2_INSITU_LARYNX_EXALLC

Endpoint definition

↥

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

None

-

2. Check conditions

  • not C3_LARYNX
-

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — D02.0&
  • Hospital discharge: ICD-9 — 2310
  • Cause of death: ICD-10 — D02.0&
  • Cause of death: ICD-9 — 2310
  • Cancer registry: Topography ICD-O-3 — C32
  • Cancer registry: Morphology ICD-O-3 — ANY
  • Cancer registry: Behaviour codes — 2

3 out of 7 registries used, show all original rules.

-

4. Check minimum number of events

None

-

5. Include endpoints

None

-

6. Filter based on genotype QC (FinnGen only)

None

-

Control definitions (FinnGen only)

Control exclude
C3_CANCER, C3_CANCER_WIDE

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF9
Parent code in ICD-10
D02
Name in latin
Carcinoma in situ bronchi

Case counts by codes

↥

FinnGen case counts by registry codes:

No upset plot: script not run.

No upset table: script not run.

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population - - -
Only index persons - - -
Unadjusted period prevalence (%)
Whole population - - -
Only index persons - - -
Median age at first event (years)
Whole population - - -
Only index persons - - -

-FinnGen-

Key figures

All Female Male
Number of individuals 58 11 47
Unadjusted period prevalence (%) 0.02 0.00 0.02
Median age at first event (years) 64.56 38.69 70.62

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
56
Matched controls
559
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
DQB10
NOMESCO Finland
Endoscopic excision of lesion of larynx
145.3
29.3
29
*
UDQ12
NOMESCO Finland
Flexible laryngoscopy
56.5
25.8
30
11
C32.0
ICD-10 Finland
Malignant neoplasm: Glottis
+∞
24.8
22
*
D14.1
ICD-10 Finland
Benign neoplasm: Larynx
126.3
22.7
23
*
DQA10
NOMESCO Finland
Biopsy of larynx
+∞
22.4
20
*
D02.0
ICD-10 Finland
Carcinoma in situ: Larynx
+∞
20.0
18
*
8070/2-C32.0
ICD-O-3
Squamous cell carcinoma in situ, NOS, of glottis
+∞
18.8
17
*
D38.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Larynx
+∞
17.6
16
*
C320, 8077, 2
ICD-O-3
NA
+∞
15.3
14
*
130
Kela drug reimbursment
Malignant tumour
+∞
14.1
13
*
J37.0
ICD-10 Finland
Chronic laryngitis
39.6
13.9
17
6
J38.3
ICD-10 Finland
Other diseases of vocal cords
91.2
13.3
14
*
ZXC10
NOMESCO Finland
Use of laser
36.4
12.9
16
6
WF002
NOMESCO Finland
Radical radiotherapy
+∞
11.9
11
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
9.6
9
*
A03FA01
ATC
metoclopramide; systemic, rectal
13.0
9.6
17
18
UDQ22
NOMESCO Finland
Microlaryngoscopy
29.8
9.4
12
5
EP1AE
NOMESCO Finland
Neck ultrasound examination
20.6
9.1
13
8
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
8.5
8
*
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
5.5
7.7
27
81
2310A
ICD-9 Finland
Carcinoma in situ of respiratory system, Larynx
+∞
7.4
7
*
C32.9
ICD-10 Finland
Malignant neoplasm: Larynx, unspecified
+∞
7.4
7
*
UDH02
NOMESCO Finland
Rhinopharyngoscopy
16.7
7.2
11
8
WX404
NOMESCO Finland
Intravenous generell anesthesy
5.9
7.2
22
55
XX3DW
NOMESCO Finland
Time consuming IT work
13.3
6.6
11
10
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
6.4
6
*
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
+∞
6.4
6
*
8070/2-C32.9
ICD-O-3
Squamous cell carcinoma in situ, NOS, of larynx, NOS
+∞
6.4
6
*
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
13.2
6.1
10
9

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
33
112
5.52
9.66
4.0
1.5
—
—
—
0
0
11
13
10.21
8.76
1.7
1.2
—
—
—
0
0
36
190
3.36
4.78
11.8
10.9
1.3
1.3
inr
0.07
11
54
28
143
2.85
3.70
7.4
4.4
—
—
—
0
0
43
278
3.11
3.61
5.1
3.9
—
—
—
0
0
26
129
2.84
3.60
5.4
4.1
—
—
—
0
0
12
38
3.72
3.44
2.7
3.1
—
—
—
0
0
24
117
2.79
3.41
3.2
2.2
—
—
—
0
0
16
64
3.07
3.21
1.9
1.7
—
—
—
0
0
13
51
3.00
2.66
1.8
2.1
—
—
—
0
0
33
207
2.38
2.62
5.8
4.0
76.1
67.3
ng/l
0.08
28
159
9
27
3.75
2.52
1.4
1.1
—
—
—
0
0
14
61
2.71
2.37
2.4
2.4
1.6
1.5
%
0.14
14
52
15
68
2.63
2.36
4.7
3.0
0.8
0.8
mmol/l
0.07
15
63
9
31
3.24
2.18
4.6
3.1
—
—
—
0
0
10
39
2.89
2.04
1.9
2.5
68.2
66.5
g/l
—
10
33
13
65
2.29
1.64
4.1
5.4
—
—
—
0
0
28
190
1.92
1.59
3.6
4.8
0.0
0.0
estimate
—
10
32
28
190
1.92
1.59
2.9
3.5
0.0
0.0
estimate
—
9
33
7
27
2.80
1.57
2.6
2.5
134.9
124.6
g/l
—
7
27
9
37
2.69
1.56
1.9
1.2
—
—
—
0
0
52
450
2.50
1.53
31.5
16.8
92.1
87.9
umol/l
0.19
52
450
35
258
1.90
1.53
5.7
4.9
7.8
7.1
mmol/l
0.50
35
238
28
193
1.87
1.49
3.0
3.5
0.0
0.0
estimate
—
10
28
22
140
1.92
1.49
6.3
5.6
—
—
—
0
0
9
40
2.47
1.48
1.2
1.5
—
—
—
0
0
6
22
2.92
1.47
1.8
2.2
10.1
10.8
g/l
—
6
17
6
22
2.92
1.47
2.8
2.9
27.6
25.0
mmol/l
—
6
22
6
22
2.92
1.47
3.3
2.5
—
—
—
0
0
9
41
2.41
1.45
1.8
3.7
25.7
6.5
umol/l
—
9
35
7
29
2.60
1.44
5.4
4.3
1.2
1.2
mmol/l
—
7
24
52
451
2.48
1.38
27.0
12.9
—
—
—
0
0
8
34
2.56
1.35
2.1
1.6
—
—
—
0
0
6
24
2.67
1.34
1.0
1.5
—
—
—
0
0
5
19
2.78
1.24
2.6
1.8
2.0
1.0
%
—
5
19
5
19
2.78
1.24
2.6
1.8
0.7
0.5
%
—
5
19
5
19
2.78
1.24
4.2
4.4
1.0
0.9
%
—
5
19
39
309
1.80
1.24
4.5
4.5
—
—
—
0
0
17
106
1.85
1.20
3.9
3.1
—
—
—
0
0
5
20
2.64
1.17
4.2
4.3
1.3
1.6
%
—
5
20
39
312
1.76
1.17
4.8
3.9
15.7
12.2
mm/h
0.47
33
283
17
109
1.79
1.09
3.5
3.6
0.0
0.0
estimate
—
9
29
9
48
2.03
1.06
3.3
3.2
3.0
2.0
mmol/l
—
9
35
36
286
1.68
1.06
6.5
4.1
1.6
2.2
ug/l
1.01
31
252
26
190
1.67
1.06
2.2
2.0
98.9
89.0
pmol/l
0.85
19
103
22
159
1.62
0.91
4.5
4.4
2.4
10.5
mg/mmol
1.95
13
104
17
117
1.64
0.84
5.2
2.6
—
—
—
0
0
17
118
1.62
0.81
2.9
2.9
—
—
—
0
0
5
23
2.28
0.78
2.0
4.7
—
—
—
0
0
7
40
1.85
0.74
2.3
4.2
—
—
—
0
0
20
148
1.54
0.73
2.7
3.5
—
—
—
0
0
15
104
1.60
0.71
2.1
2.0
2.5
2.9
mg/l
0.31
15
89
5
27
1.93
0.70
1.0
1.3
—
—
—
0
0
41
356
1.52
0.68
21.8
14.7
39.3
39.4
%
0.03
20
228
20
153
1.47
0.62
3.1
3.3
60.4
86.5
mg/l
0.20
14
98
0
19
0.00
0.61
0.0
1.1
—
—
—
0
0
16
121
1.45
0.51
6.0
4.2
7.4
7.4
ph
—
6
16
0
15
0.00
0.42
0.0
1.1
—
—
—
0
0
0
17
0.00
0.41
0.0
15.9
—
—
—
0
0
12
90
1.42
0.40
9.3
5.3
—
—
—
0
0
5
36
1.42
0.39
3.0
9.0
—
—
—
0
0
8
62
1.34
0.30
1.6
2.2
4.3
9.0
ug/l
—
8
50
8
63
1.31
0.29
1.9
2.9
2.3
2.1
g/l
—
8
57
13
156
0.79
0.25
3.2
2.9
0.8
0.8
ug/l
—
7
115
5
37
1.38
0.24
3.0
8.5
9.9
11.4
mmol/l
—
5
37
5
38
1.34
0.24
1.2
2.9
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
18
160
1.18
0.16
3.5
2.1
303.0
245.9
u/l
0.17
18
147
11
93
1.23
0.16
1.9
1.3
—
—
—
0
0
36
340
1.16
0.15
31.1
16.8
14.1
13.8
%
1.04
36
333
16
143
1.16
0.13
4.1
3.5
—
—
—
0
0
8
73
1.11
0.08
2.0
2.7
9.3
12.2
umol/l
—
8
64
17
164
1.05
0.00
3.6
2.7
193.2
164.5
ug/l
0.18
17
147
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
2.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
49.8
—
0
5
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
5
54
0.92
0.00
1.8
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
9
90
1.00
0.00
1.6
3.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint CD2_INSITU_LARYNX_EXALLC and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have CD2_INSITU_LARYNX_EXALLC.

N-year risk Females Males
1 No data No data
5 No data No data
10 No data No data
15 No data No data
20 No data No data

Relationships between endpoints

↥

Index endpoint: CD2_INSITU_LARYNX_EXALLC – Carcinoma in situ of larynx

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data